Age

Sex

BMI

G

Viral load

(log)

F

Statut

DAA

Posology

DAA

Duration

(weeks)

Drug inter

Failure moment

VR

NS3

VR

NS5A

Drugs resistance

P1

42

M

18

1b

5, 3

F1

Naïve

SOF

+

LED

400 mg/jr

+

90 mg/jr

12

No

M6 post-

Treatment

none

Y93H

L31M+

LED

P2

71

F

22

2L

6, 31

F4

Naïve

SOF

+

RBV

400 mg/jr

+

800 mg/jr

24

No

M6 post-

Treatment

none

Not

amplifiable

P3

60

F

21

1b

6, 15

F2

Naïve

SOF

+

LED

400 mg/jr

+

90 mg/jr

12

No

M3 post-

Treatment

none

28L, 30T,

31V, 58S,

93H

LED, DACLA, VELPA, ELBAS

OMBIT, PIBR↓

P4

82

F

28

1d

6

F2

Naïve

SOF

+

LED

400 mg/jr

+

90 mg/jr

12

yes

PPI

During treatment

(M3)

none

28V, 30A,

93N

LED, DACLA, ELBAS

VELPA↓, PIBR↓

P5

56

M

28

1b

6, 43

F4

Pre-

Treated

SOF

+

LED

400 mg/jr

+

90 mg/jr

12

yes

CCI (amlodipin)

Non- responders

(Q80k)

Q24k, L28T,

R30S

LED, DACLA, ELBAS

OMBIT, SIMEP, VELPA↓